Eberconazole - Pharmacological and clinical review

Moodahadu-Bangera, Latha Subramanya; Martis, Jacintha; Mittal, Rajan; Krishnankutty, Binny; Kumar, Naveen; Bellary, Shantala; Varughese, Sunoj; Rao, Parinitha K

doi:10.4103/0378-6323.93651

Cited by 18 publications

(18 citation statements)

References 8 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Phase II and III clinical studies revealed that multiple applications of 1% cream to human skin resulted in pruritis, local cutaneous irritation, skin dryness, erythema and reddening of skin. This might be due to excessive accumulation in the epidermis and dermis of the lipophilic drug [16]. In addition, the systemically absorbed fraction of the dose is excreted in the urine [17].…”

mentioning

confidence: 99%

Investigation of Ethyl Cellulose Microsponge Gel for Topical Delivery of Eberconazole Nitrate for Fungal Therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Investigation of Ethyl Cellulose Microsponge Gel for Topical Delivery of Eberconazole Nitrate for Fungal Therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[5556] The uncomfortable truth is that all these changes in pattern of prescriptions are happening, even if to the benefit of the patient, without a simple potassium hydroxide (KOH) examination in most patients especially in the case of private practitioners who form the majority of caregivers. Although it is thought to be essential in many countries, it is not practical because it is time consuming and most often the doctors do not have trained assistants to do this.…”

Section: Commonly Employed Treatment Measuresmentioning

confidence: 99%

The great Indian epidemic of superficial dermatophytosis: An appraisal

Verma¹,

Madhu

2017

Indian J Dermatol

131

View full text Add to dashboard Cite

“…It prevents fungal growth by inhibiting lanosterol 14α-demethylase enzyme that is responsible for the formation of 14α-methylsterols (precursor of ergosterols). [ 5 ] Eberconazole exerts fungicidal or fungistatic activity depending upon concentration, being fungicidal at higher and fungistatic at lower concentrations. [ 5 ] Topical eberconazole has good local and general tolerability without detectable systemic drug levels.…”

Section: Introductionmentioning

confidence: 99%

“…[ 5 ] Eberconazole exerts fungicidal or fungistatic activity depending upon concentration, being fungicidal at higher and fungistatic at lower concentrations. [ 5 ] Topical eberconazole has good local and general tolerability without detectable systemic drug levels. [ 6 ]…”

Section: Introductionmentioning

confidence: 99%

A comparative study of efficacy and safety of eberconazole versus terbinafine in patients of tinea versicolor

2018

View full text Add to dashboard Cite

Background:Tinea versicolor (TV) is characterised by the appearance of maculosquamous lesions sometimes associated with mild erythema and pruritus in characteristic areas of the body. Eberconazole and terbinafine though drugs of different classes provide both mycological and clinical cure.Aim:This study aims to compare the efficacy and safety of eberconazole versus terbinafine in patients of TV.Materials and Methods:An open-label, randomised, comparative clinical trial was conducted on 60 patients. The patients were randomly divided into two study groups. Group A: Eberconazole 1% cream once daily and Group B: Terbinafine 1% cream once daily for 2 weeks. Efficacy assessment was done by observing signs and symptoms, i.e., Physician assessment 4-point scale, microscopic KOH examination, Wood's lamp examination, global clinical response assessment, and patient's assessment on visual analog scale at the end of 2 weeks and subsequently patients were reassessed at the end of 4 and 8 weeks to check any relapse. Safety assessment was also done.Results:There was a significant improvement in all the parameters in both groups over a period of 2 weeks. Both the treatment groups, i.e., eberconazole and terbinafine were found to be safe and efficacious at the end of 2 weeks, and no statistically significant difference was observed between the two groups regarding complete cure, i.e., mycological and clinical cure (80% vs. 63.33%), respectively. However, early response (at the end of week 1) was observed with eberconazole. No relapse was seen with eberconazole, but one patient had relapse at 8 weeks with terbinafine. Both drugs had similar safety profile.Conclusion:Although both the drugs cured the disease, eberconazole showed better response as clinical cure and mycological cure were observed earlier and no patient relapsed in the follow-up.

show abstract

Eberconazole - Pharmacological and clinical review

Cited by 18 publications

References 8 publications

Investigation of Ethyl Cellulose Microsponge Gel for Topical Delivery of Eberconazole Nitrate for Fungal Therapy

Investigation of Ethyl Cellulose Microsponge Gel for Topical Delivery of Eberconazole Nitrate for Fungal Therapy

The great Indian epidemic of superficial dermatophytosis: An appraisal

A comparative study of efficacy and safety of eberconazole versus terbinafine in patients of tinea versicolor

Contact Info

Product

Resources

About